ACRIGEN BIOSCIENCES, INC. competitors & alternatives

Biotechnology

Excision BioTherapeutics Inc. is a San Francisco-based clinical-stage biotechnology company focused on developing advanced gene editing therapeutics to treat infectious diseases.

BreezeBioBiotechnologyUnited States

70% match

Biotechnology

BreezeBio is a biotechnology company headquartered in the South San Francisco area of California that develops precision genetic medicines.

Azalea TherapeuticsBiotechUnited States

69% match

Biotech

Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.

Encoded TherapeuticsBiotechUnited States

69% match

Biotech

Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.

Biotechnology

Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.

Epicrispr BiotechnologiesBiotechnologyUnited States

68% match

Biotechnology

Epicrispr Biotechnologies is a pioneering therapeutics company dedicated to developing advanced genetic medicines. The organization focuses on scientific research, platforms, and clinical pipelines to treat serious diseases.

Biotechnology

Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.

Biotech

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

KiraGen BioBiotechnologyUnited States

67% match

Biotechnology

KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.

Biotech

Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.

Biotechnology

Mammoth Biosciences is a biotechnology company based in Brisbane, California developing diagnostic tests using CRISPR-Cas12a and CRISPR-based therapies using its proprietary ultra-small CRISPR systems. Several CRISPR-Cas systems identified through the company's metagenomics-based protein discovery platform, including members of the Casφ and Cas14 families of CRISPR-associated enzymes, have demonstrated potential for therapeutic genome editing in in vivo settings.

Arbor Biotechnologies, Inc.BiotechnologyUnited States

66% matchPrivate

Biotechnology

Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.